Semaglutide versus tirzepatide represents the most common comparison
For people with diabetes taking insulin or sulfonylureas, there is an increased risk of hypoglycaemia when adding Wegovy, and dose adjustments of these medications may be needed
Refreshingly easy
Though not every anti-diabetic medicine is beneficial for weight reduction in non-diabetics, GLP-1-RAs, particularly semaglutide, stand out for their pleiotropic effects in this regard [7, 9, 14, 15]
Currently, yes semaglutide has proven cardiovascular benefit from the SELECT trial (2023), which demonstrated significant reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients with obesity and established heart disease